Do proton‑pump inhibitors prevent subsequent upper gastrointestinal bleeding in patients with portal‑hypertension‑related variceal bleeds?

PPIs for Post-Endoscopic Treatment Ulcer Prevention, Not Variceal Rebleeding Prevention

PPIs should be used following endoscopic treatment of variceal bleeding to prevent post-procedure ulcer bleeding, not to prevent subsequent variceal rebleeding. 1

The Critical Distinction

The evidence clearly separates two different bleeding risks:

1. Post-Procedure Ulcer Bleeding (PPI Indicated)

• Endoscopic variceal ligation (EVL) and endoscopic variceal obturation (EVO) create iatrogenic ulcers at treatment sites
• PPIs reduce post-EVL ulcer size and ulcer bleeding rates 1
• The 2020 KASL guidelines explicitly recommend: "A PPI can be used following endoscopic treatments to prevent post-procedure ulcer bleeding" (B2 recommendation) 1
• One retrospective study showed PPI use decreased rebleeding risk following EVO (OR 0.554; 95% CI 0.352-0.873) 2

2. Variceal Rebleeding (PPI NOT Indicated)

• Variceal rebleeding is prevented by addressing portal hypertension, not gastric acid
• Effective interventions include: non-selective beta-blockers (NSBBs) + repeat EVL, repeat EVO, TIPS, or retrograde transvenous obliteration 1
• PPIs do not address the underlying pathophysiology of portal hypertension

Evidence Quality and Nuances

The most recent 2026 meta-analysis 3 definitively shows:

• Unadjusted analyses suggested benefit, but rigorous RCT data showed NO significant effect on post-EBL bleeding or mortality
• Trial sequential analysis confirmed RCT evidence is underpowered and inconclusive
• Current evidence is insufficient to support routine PPI use after EBL

However, an earlier 2021 meta-analysis 4 suggested PPIs used >1 month may decrease rebleeding after endoscopic therapy, though this did not impact bleeding-related mortality.

Critical Care Context

In critically ill ACLF patients with portal hypertensive bleeding, the 2023 Critical Care Medicine guidelines recommend: "We recommend using proton pump inhibitors (PPIs) in critically ill ACLF patients with portal hypertensive bleeding (Strong recommendation, low quality of evidence)" 5. The rationale cites mechanisms from nonvariceal UGIB (platelet aggregation, fibrin clot stabilization), though whether these benefits extend to variceal bleeding remains unclear.

Important Caveats

Long-term PPI use in cirrhosis carries risks:

• Increased risk of spontaneous bacterial peritonitis 1
• Increased risk of hepatic encephalopathy 1
• PPIs should be used with caution and for limited duration 1

Common pitfall: Prescribing PPIs indefinitely after variceal bleeding without a clear indication. A 2025 study found 53.6% of cirrhotic patients had inappropriate PPI use, often for preventing PHG or variceal bleeding (16.42%) or prolonged use post-EVL (29.1%) 6.

Practical Algorithm

After endoscopic treatment of variceal bleeding:

1. Start PPI to prevent post-procedure ulcer bleeding
2. Duration: Continue until post-procedure ulcers heal (typically 2-4 weeks, not >1 month unless specific indication)
3. Discontinue PPI once ulcers healed unless separate indication exists (e.g., peptic ulcer disease)
4. For variceal rebleeding prevention: Implement NSBB + repeat EVL, not PPIs 1